These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9364247)
1. Effects of tamoxifen on GH and IGF-I levels in acromegaly. Cozzi R; Attanasio R; Oppizzi G; Orlandi P; Giustina A; Lodrini S; Da Re N; Dallabonzana D J Endocrinol Invest; 1997 Sep; 20(8):445-51. PubMed ID: 9364247 [TBL] [Abstract][Full Text] [Related]
2. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer. De Marinis L; Mancini A; Izzi D; Bianchi A; Giampietro A; Fusco A; Liberale I; Rossi S; Valle D Clin Endocrinol (Oxf); 2000 Jun; 52(6):681-5. PubMed ID: 10848871 [TBL] [Abstract][Full Text] [Related]
3. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809 [TBL] [Abstract][Full Text] [Related]
4. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010 [TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients. Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244 [TBL] [Abstract][Full Text] [Related]
9. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218 [TBL] [Abstract][Full Text] [Related]
10. Cabergoline in the treatment of acromegaly: a study in 64 patients. Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544 [TBL] [Abstract][Full Text] [Related]
11. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients. Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479 [TBL] [Abstract][Full Text] [Related]
12. [The place of insulin-like growth factor I in the diagnosis of acromegaly]. Dohán O; Góth M; Szabolcs I; Kovács L; Kovács Z; Szilágyi G Orv Hetil; 1993 Oct; 134(42):2301-3. PubMed ID: 8233444 [TBL] [Abstract][Full Text] [Related]
13. Effect of growth hormone and insulin-like growth factor I on urinary albumin excretion: studies in acromegaly and growth hormone deficiency. Hoogenberg K; Sluiter WJ; Dullaart RP Acta Endocrinol (Copenh); 1993 Aug; 129(2):151-7. PubMed ID: 8372600 [TBL] [Abstract][Full Text] [Related]
14. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Quabbe HJ; Plöckinger U J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912 [TBL] [Abstract][Full Text] [Related]
15. Raloxifene lowers IGF-I levels in acromegalic women. Attanasio R; Barausse M; Cozzi R Eur J Endocrinol; 2003 Apr; 148(4):443-8. PubMed ID: 12656665 [TBL] [Abstract][Full Text] [Related]
16. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Bates AS; Evans AJ; Jones P; Clayton RN Clin Endocrinol (Oxf); 1995 Apr; 42(4):417-23. PubMed ID: 7750196 [TBL] [Abstract][Full Text] [Related]